Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab

Yoshihito Sakanishi, Ami Lee, Ayumi Usui-Ouchi, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the clinical efficacy of low-frequency intravitreal ranibizumab to treat macul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sakanishi Y, Lee A, Usui-Ouchi A, Ito R, Ebihara N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	etinal vein occlusion ranibizumab macula edema BRVO CRVO Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/40108e277fc9485a9f87b7e0fefdf15a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:40108e277fc9485a9f87b7e0fefdf15a
record_format	dspace
spelling	oai:doaj.org-article:40108e277fc9485a9f87b7e0fefdf15a2021-12-02T00:24:01ZTwelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab1177-5483https://doaj.org/article/40108e277fc9485a9f87b7e0fefdf15a2016-06-01T00:00:00Zhttps://www.dovepress.com/twelve-month-outcomes-in-patients-with-retinal-vein-occlusion-treated--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Yoshihito Sakanishi, Ami Lee, Ayumi Usui-Ouchi, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the clinical efficacy of low-frequency intravitreal ranibizumab to treat macular edema due to retinal vein occlusion (RVO).Patients and methods: This was a retrospective examination of cases that received intravitreal ranibizumab for untreated RVO over a period of 12 months. Instead of the conventional three monthly injections, injections were given once during the introductory period. If the recurrence of macular edema was diagnosed during the monthly visit, additional injections were given as needed. There were 21 eyes of 21 patients with branch RVO (BRVO) and ten eyes of ten patients with central RVO (CRVO). The parameters examined included the number of injections over the 12-month period, improvements in best-corrected visual acuity (BCVA), and the central macular thickness (CMT). For BRVO, preinjection parameters that had an effect on the prognosis of BCVA after the 12-month period were also examined.Results: The total mean number of injections over the 12-month period was 3.4 for CRVO and 2.1 for BRVO. For CRVO, the BCVA in log minimum angular resolution changed from a preinjection value of 0.80 to 0.55 at 12 months. For BRVO, the change was from 0.51 to 0.30. For all diseases, BCVA improved after 12 months compared with the preinjection values (P<0.05). There was improvement in the CMT, and the CRVO changed from 765.0 µm at preinjection to 253.5 µm 12 months later. BRVO changed from 524.1 to 250.1 µm, and preinjection BCVA was associated with a prognosis of visual acuity after 12 months of the initial injection (P=0.0485).Conclusion: Even with a low number of injections during the introductory period, there were still improvements in both visual acuity and CMT in RVO patients after 12 months, indicating that it was an effective treatment. Keywords: retinal vein occlusion, IVR, macular edema, BRVO, CRVOSakanishi YLee AUsui-Ouchi AIto REbihara NDove Medical Pressarticleetinal vein occlusionranibizumabmacula edemaBRVOCRVOOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 1161-1165 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	etinal vein occlusion ranibizumab macula edema BRVO CRVO Ophthalmology RE1-994
spellingShingle	etinal vein occlusion ranibizumab macula edema BRVO CRVO Ophthalmology RE1-994 Sakanishi Y Lee A Usui-Ouchi A Ito R Ebihara N Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
description	Yoshihito Sakanishi, Ami Lee, Ayumi Usui-Ouchi, Rei Ito, Nobuyuki Ebihara Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan Purpose: The purpose of this study was to determine the clinical efficacy of low-frequency intravitreal ranibizumab to treat macular edema due to retinal vein occlusion (RVO).Patients and methods: This was a retrospective examination of cases that received intravitreal ranibizumab for untreated RVO over a period of 12 months. Instead of the conventional three monthly injections, injections were given once during the introductory period. If the recurrence of macular edema was diagnosed during the monthly visit, additional injections were given as needed. There were 21 eyes of 21 patients with branch RVO (BRVO) and ten eyes of ten patients with central RVO (CRVO). The parameters examined included the number of injections over the 12-month period, improvements in best-corrected visual acuity (BCVA), and the central macular thickness (CMT). For BRVO, preinjection parameters that had an effect on the prognosis of BCVA after the 12-month period were also examined.Results: The total mean number of injections over the 12-month period was 3.4 for CRVO and 2.1 for BRVO. For CRVO, the BCVA in log minimum angular resolution changed from a preinjection value of 0.80 to 0.55 at 12 months. For BRVO, the change was from 0.51 to 0.30. For all diseases, BCVA improved after 12 months compared with the preinjection values (P<0.05). There was improvement in the CMT, and the CRVO changed from 765.0 µm at preinjection to 253.5 µm 12 months later. BRVO changed from 524.1 to 250.1 µm, and preinjection BCVA was associated with a prognosis of visual acuity after 12 months of the initial injection (P=0.0485).Conclusion: Even with a low number of injections during the introductory period, there were still improvements in both visual acuity and CMT in RVO patients after 12 months, indicating that it was an effective treatment. Keywords: retinal vein occlusion, IVR, macular edema, BRVO, CRVO
format	article
author	Sakanishi Y Lee A Usui-Ouchi A Ito R Ebihara N
author_facet	Sakanishi Y Lee A Usui-Ouchi A Ito R Ebihara N
author_sort	Sakanishi Y
title	Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
title_short	Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
title_full	Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
title_fullStr	Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
title_full_unstemmed	Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
title_sort	twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/40108e277fc9485a9f87b7e0fefdf15a
work_keys_str_mv	AT sakanishiy twelvemonthoutcomesinpatientswithretinalveinocclusiontreatedwithlowfrequencyintravitrealranibizumab AT leea twelvemonthoutcomesinpatientswithretinalveinocclusiontreatedwithlowfrequencyintravitrealranibizumab AT usuiouchia twelvemonthoutcomesinpatientswithretinalveinocclusiontreatedwithlowfrequencyintravitrealranibizumab AT itor twelvemonthoutcomesinpatientswithretinalveinocclusiontreatedwithlowfrequencyintravitrealranibizumab AT ebiharan twelvemonthoutcomesinpatientswithretinalveinocclusiontreatedwithlowfrequencyintravitrealranibizumab
_version_	1718403733559181312

Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab

Ejemplares similares